CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Bill & Melinda Gates Foundation

EcoR1 Capital

SR One

Wellington Capital Management

New Leaf Venture Partners

Franklin Templeton

Clough Capital Partners

New Enterprise Associates

Abingworth

Versant Ventures

Vertex Pharmaceuticals

CRISPR Therapeutics

The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the conditional approval of the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia. 

#Breaking: The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease. Learn more: https://bit.ly/4apMw9p

Today, we provided an update on our immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates and we announced expansion into autoimmune disease. Learn more here: https://bit.ly/4a8zpsM

#Breaking: The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves the treatment for #SickleCellDisease and #BetaThalassemia in Great Britain. This a historic scientific milestone arising out of our collaboration with Vertex. Learn more: crisprtx.com

Today was an exciting day as Dr. PK Morrow, CRISPR Therapeutics Chief Medical Officer, presented preclinical data on our investigational programs for the treatment of cardiovascular disease in two oral sessions at the American Heart Association Scientific Sessions. Learn more: https://bit.ly/47oCkLX #AHA23

Renova Therapeutics is a San Diego-based biopharmaceutical company and an industry leader in gene therapy, pursuing the development of treatments for congestive heart failure (CHF) and other chronic diseases.

Renova Therapeutics

CRISPR Therapeutics AG is a Swiss–American biotechnology company that pioneers the use of the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has a diverse portfolio across disease areas including hemoglobinopathies, oncology, diabetes, and cardiovascular disease.

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 7, 2024 7:47 PM	9ca66c9d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 7, 2024 7:47 PM	675471cb
company summary	general
signals	general	Mar 7, 2024 7:47 PM	5fa1932f
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 7, 2024 7:47 PM	99340e93
translate crunchbase fundingrounds	general
peers	general	Mar 7, 2024 7:47 PM	ba904402
news basic	general	Mar 7, 2024 7:47 PM	776074c0
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CRISPRTX

CRISPR Therapeutics AG

Last Close

46.29

22/11 21:00

Market Cap

4.72B

Beta: -

Volume Today

1.50M

Avg: -